ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.
What happened
FDA inspected ABS Corporation’s drug manufacturing facility in Omaha, Nebraska, from January 12th to 16th 2026. FDA found that the company released batches with confirmed out-of-specification results, failed to adequately test incoming components, used expired raw material that failed retesting, and lacked adequate process validation. The company responded to the inspection findings on January 30, 2026, but FDA found the response inadequate.
What FDA found
The company released drug batches with confirmed out-of-specification results without thoroughly investigating them or performing required corrective actions, and it hand-changed a test limit without justification.
21 CFR 211.192The company did not adequately test incoming components for identity and other specifications, did not withhold components until release, and used expired raw material that failed retesting before releasing the resulting batches.
21 CFR 211.84(a) and 211.84(d)The company lacked adequate written production and process-control procedures and validation records, changed specifications to fit failing results, and distributed products without evidence of a validated process.
21 CFR 211.100(a)
What FDA wants
FDA tells ABS to respond in writing within 15 working days with corrective actions and comprehensive independent assessments of its investigation, CAPA, materials, and validation systems. FDA also recommends engaging a qualified CGMP consultant to audit the entire operation.
Who should pay attention
- veterinary drug manufacturers and contract manufacturers
- animal health brands that distribute or buy these products
- quality teams responsible for batch release and supplier qualification
This is a summary. Read the original letter on fda.gov.